Results 51 to 60 of about 1,295 (151)
Successful treatment of acyclovir‐resistant herpes simplex virus infection with amenamevir in a patient who received umbilical cord blood transplantation for T‐cell prolymphocytic leukemia
eJHaemA 34‐year‐old woman received umbilical cord blood transplantation for refractory T‐cell prolymphocytic leukemia after salvage therapy with alemtuzumab.Yuma Kawamura, Nako Uchibori, Tomoya Arakawa, Tomoki Fujii, Shuto Negishi, Shiori Morikawa, Nobuaki Fukushima, Akio Kohno, Souichi Yamada, Yoshiko Fukui, Shuetsu Fukushi, Kazutaka Ozeki +11 moredoaj +1 more sourceAdvancing Antiviral Design: Integrating Natural Products, Computation and Targeted Delivery
Chemical Biology &Drug Design, Volume 108, Issue 1, July 2026.A stepwise translational framework linking natural‐product discovery, computational prioritisation, experimental validation, lead optimisation and targeted delivery is proposed to advance antiviral design. ABSTRACT
The COVID‐19 pandemic highlighted the role of rapid viral mutation and global connectivity in accelerating viral emergence and spread ...Adedayo Ayodeji Lanrewaju, Abimbola Motunrayo Folami, Saheed Sabiu, Feroz Mahomed Swalaha +3 morewiley +1 more sourceHerpes Simplex Virus Hepatitis: An Overlooked Cause of Acute Liver Failure Across a Broad Spectrum of Immunocompromise
Liver International, Volume 46, Issue 7, July 2026.ABSTRACT Background and Aims
Herpes simplex virus (HSV) infection is common worldwide, but hepatic involvement is rare. HSV hepatitis is an uncommon yet frequently catastrophic cause of acute hepatitis and acute liver failure (ALF), accounting for < 1% of ALF cases while carrying very high mortality when diagnosis and antiviral therapy are delayed ...Mario U. Mondelli, Serena Ludovisi, Angela Di Matteo, Gülşen Özkaya Şahin, William Irving, European Society of Clinical Microbiology and Infectious Diseases Study Group for Viral Hepatitis (ESGVH) +5 morewiley +1 more sourceDevelopment and validation of a non-radioactive DNA polymerase assay for studying cytomegalovirus resistance to foscarnet [PDF]
, 2007 International audiencePhenotypic characterisation of the human cytomegalovirus (HCMV) pUL54 DNA polymerase is a useful tool for testing for mutations in the UL54 gene thought to render HCMV resistant to foscarnet.F. Petit, Mazeron, Marie-Christine, M.C. Mazeron, Petit, Françoise, Sanson Le Pors, Marie-José, S. Alain, M.J. Sanson Le Pors, Ducancelle, Alexandra, Alain, Sophie, A. Ducancelle +9 morecore +1 more sourceCMV retinitis in a stem cell transplant recipient treated with foscarnet intravitreal injection and CMV specific immunoglobulins
Therapeutic Advances in Hematology, 2020 Cytomegalovirus (CMV) retinitis (CMVR) has been reported rarely in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). In addition, little is known about strategies for ophthalmic surveillance and adequate antiviral treatment ...Francesco Vassallo, Raffaele Nuzzi, Ilaria Cattani, Chiara Dellacasa, Luisa Giaccone, Francesco Giuseppe De Rosa, Rossana Cavallo, Giorgia Iovino, Lucia Brunello, Benedetto Bruno, Alessandro Busca +10 moredoaj +1 more sourceEuropean Recommendations for Transitioning the Care of Patients With Multiple Myeloma Treated With B‐Cell Maturation Antigen Bispecific Antibodies From Academic Hospitals to Community‐Based Centers and for Outpatient Step‐Up Dosing
eJHaem, Volume 7, Issue 3, June 2026.ABSTRACT Introduction
Safe outpatient delivery of B‐cell maturation antigen–targeting bispecific antibodies (BCMA‐BsAbs) in multiple myeloma (MM) is challenging, particularly during step‐up dosing (SUD). Standardized guidance for European community practice is limited.María‐Victoria Mateos, Elena Zamagni, Massimo Gentile, Rachel Hall, Florence Lachenal, Mónica López Riñon, Rakesh Popat, Christof Scheid, Thomas Wolff, Isabel Perez‐Cruz, Mohamad Mohty +10 morewiley +1 more sourceMorbidity and Toxic Effects Associated With Ganciclovir or Foscarnet Therapy in a Randomized Cytomegalovirus Retinitis Trial
, 1995 BACKGROUND: The Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial compared the use of either ganciclovir or foscarnet for the initial treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.Conway, Brian, Jacobson, Mark, Kimbrell, Chris, Apuzzo, Linda, Fainstein, Victor, Jabs, Douglas A, Meinert, Curtis L, Collison, Betty J, Clark, Tom, Henderly, Dale, Dieterich, Douglas, Lewis, Richard A, Nussenblatt, Robert, Klemm, Amy C, Grizzle, James, Fink, Nancy, Rickman, Leland, Feinberg, Judith, Vandenbroucke, Ruth, Thomas, Suzanne, Mowery, Richard, Jampol, Lee, Saah, A, Freitag, Ginger, Sacks, Henry, Kachadoorian, Harry, Samo, Tobias, Mendez, Paul, Ellenberg, Susan, Webb, Rene, Holbrook, Janet T, Brothers, Rosemary, Frost, Kevin, MacArthur, Lesley J, Seiff, Stuart, Hubbard, Larry, Binder, Karen L, Coleson, Laura, Gerczak, Charlotte, Larson, James, Gross, Ronald, Leslie, Jo, Freeman, William R, Gittinger, John, Meinert, J. L, Peyman, Gholam, Jordan, Colin, Bartlett, John, Espinal, Millie, Korvick, Joyce, Dodge, John, Isaacson, Milana R, Holland, Gary N, Hurlburt, Dolores, Hoffman, Jacqueline, Brown-Bellamy, Jude, Davis, Janet, Kline, Joan M, Min, Yuan-I, Van Natta, Mark L, Simanello, Mary Ann, Barron, Bruce, Agres-Segal, Maria, Miner, Kathleen, O'Donnell, James, Quiceno, Jose I, Franklin, Rudolph, Markowitz, Jan A, Magli, Yvonne, Wise-Campbell, Susanne, Smith, Michael, Cheung, Tony W, Tuttle, Colette, Hardy, W. David, Sandford, Gordon R, Sternberg, Alice L, Teich, Steven, Friedberg, Dorothy N, Freeman, William, Owens, Rosetta M, Davis, Matthew D, Eldred, Lois, Stewart, Gary, Heinemann, Murk-Hein, Haubrich, Richard, Cheeseman, Sarah H, Brown, Vivian E, Meixnert, Linda, Peterson, Timothy J, Armstrong, Jane, Vanderhoof-Young, Marilyn, Mills, John, Naughton, Kathleen, Jones, Camara P, Polsky, Bruce, Friedman, Alan H, Welch, Lisa, Spector, Stephen, Severin, Colette, Levine, Charlene R, Hughes, Robert, Justin, Norma, Singer, Stephen, Kastorff, Linda, Greenspan, Deborah, Nowakowski, Deborah J, Tolson, Karen, Dunn, J. P, Clogston, Pamela, Chuang, Elaine, Smith, Harmon, Clogston, Pamela S, Chafey, Suzette, Squires, Kathleen, Brookmeyer, Ronald, Flynn, Thomas, Addessi, Adrienne, King, Rosemary, Tonascia, James, Brown, Byron W, Sattler, Fred, Irvine, Alexander, Murphy, Robert, Donithan, Michele, Phair, John, Le-Count, Cynthia, Weinberg, David, Wanner, Maxine, Fall, Holly, Stevens, Maria +129 morecore +1 more sourceProtective Effect of Vitamin E Against Vancomycin‐Induced Nephrotoxicity: A Large‐Scale Electronic Medical Record Study From Japan
Basic &Clinical Pharmacology &Toxicology, Volume 138, Issue 6, June 2026.ABSTRACT
Vancomycin (VCM) is essential for treating methicillin‐resistant Staphylococcus aureus infections, but its use is limited by vancomycin‐induced nephrotoxicity (VIN). Although preclinical and small clinical studies suggest a protective role for vitamin E, real‐world evidence remains limited.Satoru Nakanishi, Shungo Imai, Megumi Saito, Hayato Kizaki, Haru Iino, Masami Tsuchiya, Satoko Hori +6 morewiley +1 more sourceCharacterisation of Foscarnet-Resistant Strains of Human Immunodeficiency Virus Type 1
, 1995 Foscarnet is a broad spectrum viral DNA polymerase inhibitor active in vitro and in vivo against human immunodeficiency virus type 1 (HIV-1). Strains of HIV-1 resistant to foscarnet were selected by in vitro passage in increasing concentrations of drug ...Gurusinghe, Asitha D., Bazmi, Hengameh, Hooker, David J., Tachedjian, Gilda, Deacon, Nicholas J., Mellors, John, Mills, John, Birch, Chris +7 morecore +1 more source
